Seattle Genetics

Seattle Genetics, co-founded by Clay Siegall, is a biotechnology company leading the field of antibody-drug conjugates (ADCs) for the treatment of cancer. Our technology is designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. Our lead program, ADCETRIS® (brentuximab vedotin), is the first in a new class of ADCs and, in collaboration with Takeda Pharmaceutical Company Limited, is approved in more than 55 countries. To expand on the ADCETRIS opportunity, we are conducting a broad clinical development program to evaluate its therapeutic potential in a range of other lymphoma and non-lymphoma settings. Seattle Genetics is also advancing a robust pipeline of clinical-stage programs, including SGN-CD19A, SGN-CD33A, SGN-LIV1A, SGN-CD70A, ASG-22ME, ASG-15ME and SEA-CD40. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including AbbVie, Agensys (an affiliate of Astellas), Bayer, Genentech, GlaxoSmithKline and Pfizer. Across both internal and collaborator programs, there are more than 20 ADCs in clinical development using our proprietary approach to empowering antibodies.
Company Growth (employees)
Type
Public
HQ
Bothell, US
Founded
1998
Size (employees)
890 (est)+18%
Seattle Genetics was founded in 1998 and is headquartered in Bothell, US

Key People at Seattle Genetics

Clay B. Siegall

Clay B. Siegall

Co-founder, President , CEO & Chairman
Todd E. Simpson

Todd E. Simpson

CFO
Eric Dobmeier

Eric Dobmeier

Chief Operating Officer
Vaughn Himes

Vaughn Himes

EVP, Process Sciences and Technical Operations
Chris Boerner

Chris Boerner

Executive Vice President, Commercial
Jonathan Drachman

Jonathan Drachman

Chief Medical Officer; EVP, Research and Development

Seattle Genetics Office Locations

Seattle Genetics has offices in Bothell, Washington
Bothell, US
Washington, US

Seattle Genetics Metrics

Seattle Genetics Summary

Market capitalization

$9.5 b

Closing share price

$68
Seattle Genetics's current market capitalization is $9.5 b.

Seattle Genetics Financials

Seattle Genetics's revenue is $269.3 m in FY, 2013 which is a 6.1% decrease from the previous period.
FY, 2013FY, 2014FY, 2015FY, 2016

Revenue

$269.3 m$286.8 m$336.8 m$418.1 m

Revenue growth, %

6.5%17.5%24.2%

Gross profit

$255.5 m$269.2 m$312.3 m

Operating expense total

$318.4 m$346.6 m$433.3 m

EBIT

($62.9 m)($77.4 m)($121 m)

Net Income

($62.5 m)($76.1 m)($120.5 m)($140.1 m)

Operating cash flow

$9.5 m($7.2 m)$45.3 m

Seattle Genetics Market Value History

Seattle Genetics Job Categories

Seattle Genetics Online Presence

Seattle Genetics News

Seattle Genetics Company Life

You may also be interested in